Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS AFTER PLEURECTOMY/DECORTICATION

NCT04996017 is registered in ClinicalTrials.gov with Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor.

NCT NCT04996017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04996017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS AFTER PLEURECTOMY/DECORTICATION
Lead sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Phase
Phase 3
Overall status
Recruiting
Start date
December 14, 2021
Completion date
June 30, 2029
Enrollment
162 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

mesotheliomas pleural